Status:
COMPLETED
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies
Lead Sponsor:
Nohla Therapeutics, Inc.
Collaborating Sponsors:
National Heart, Lung, and Blood Institute (NHLBI)
National Cancer Institute (NCI)
Conditions:
Accelerated Phase Chronic Myelogenous Leukemia
Adult Acute Myeloid Leukemia in Remission
Eligibility:
All Genders
6-45 years
Phase:
PHASE2
Brief Summary
This phase II trial is studying the safety and potential efficacy of infusing non-human leukocyte antigen matched ex vivo expanded cord blood progenitors with one or two unmanipulated umbilical cord b...
Detailed Description
PRIMARY OBJECTIVES: I. Examine the safety and toxicity when ex vivo expanded cord blood cells are infused as an off-the-shelf non-human leukocyte antigen (HLA) matched product with the goal of provid...
Eligibility Criteria
Inclusion
- Acute myeloid leukemia:
- High risk complete response (CR)1 as evidenced by preceding myelodysplastic syndromes (MDS), high risk cytogenetics (for example, monosomy 5 or 7, or as defined by referring institution treatment protocol), \>= 2 cycles to obtain CR, erythroblastic or megakaryocytic leukemia; \>= CR2
- All patients must be in CR as defined by hematologic recovery and \< 5% blasts by morphology within the bone marrow and a cellularity of \>= 15%
- Patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the Principal Investigator, Colleen Delaney prior to enrollment
- Acute lymphoblastic leukemia:
- High risk CR1 \[for example, but not limited to: t(9;22), t(1;19), t(4;11) or other mixed lineage leukemia (MLL) rearrangements, hypodiploid\]
- Greater than 1 cycle to obtain CR
- \>= CR2
- All patients must be in CR as defined by hematologic recovery and \< 5% blasts by morphology within the bone marrow and a cellularity of \>= 15%
- Patients in which adequate marrow/biopsy specimens cannot be obtained to determine remission status by morphologic assessment, but have fulfilled criteria of remission by flow cytometry, recovery of peripheral blood counts with no circulating blasts, and/or normal cytogenetics (if applicable) may still be eligible; reasonable attempts must be made to obtain an adequate specimen for morphologic assessment, including possible repeat procedures; these patients must be discussed with the Principal Investigator, Colleen Delaney prior to enrollment
- Chronic myelogenous leukemia excluding refractory blast crisis; to be eligible in first chronic phase (CP1) patient must have failed or be intolerant to imatinib mesylate
- Myelodysplasia (MDS) International Prognostic Scoring System (IPSS) intermediate 2 (Int-2) or high risk (i.e., refractory anemia with excess myeloblasts \[RAEB\], refractory anemia with excess blasts in transformation \[RAEB-T\]) or refractory anemia with severe pancytopenia or high risk cytogenetics; blasts must be \< 10% by a representative bone marrow aspirate morphology
- Karnofsky (\>= 16 years old) \>= 70%
- Lansky (\< 16 years old) \>= 50%
- Calculated creatinine clearance must be \> 60 mL and serum creatinine =\< 2 mg/dL (adults)
- Calculated creatinine clearance must be \> 60 mL/min (children \< 18 years old)
- Total serum bilirubin must be \< 3 mg/dl
- Transaminases must be \< 3 x the upper limit of normal
- Diffusion capacity of the lung for carbon monoxide (DLCO) corrected \> 50% normal
- For pediatric patients unable to perform pulmonary function tests, oxygen (O2) saturation \> 92% on room air
- Left ventricular ejection fraction \> 45% OR shortening fraction \> 26%
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Uncontrolled viral or bacterial infection at the time of study enrollment
- Active or recent (prior 6 month) invasive fungal infection without infectious disease (ID) consult and approval
- History of human immunodeficiency virus (HIV) infection
- Pregnant or breastfeeding
- If =\< 18 years old, prior myeloablative transplant within the last 6 months
- If \> 18 years old prior myeloablative allotransplant or autologous transplant
- Extensive prior therapy including \> 12 months alkylator therapy or \> 6 months alkylator therapy with extensive radiation
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT01175785
Start Date
August 1 2010
End Date
August 1 2014
Last Update
March 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109